Fig. 8From: Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & IIChange in the CT scan percentage of lung involvement before and after of secretome administration. This treatment significantly improved the lung involvement of patients when they were discharged from hospital. Furthermore, this effect was completely different in both groups of surviving and dying patientsBack to article page